Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer

Meng Heng Hsieh, Yueh Fu Fang, Wen Cheng Chang, Han Pin Kuo, Shinn Yn Lin, Hui Ping Liu, Chih Lin Liu, Hsiu Chi Chen, Yuan Chieh Ku, Ya Ting Chen, Ya Hui Chang, Ying Tsong Chen, Bae Li Hsi, Shih Feng Tsai, Shiu Feng Huang

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Mutational analysis was performed in the kinase domain (exons 18-21) of the EGFR gene on tumor tissues of 65 non-small cell lung cancer (NSCLC) patients who had received gefitinib monotherapy. The association between EGFR gene mutation, gefitinib treatment response, and the overall survival were evaluated. In total, EGFR mutations with complex patterns were identified in 32 tumors. The overall mutation rate was 49.2% (32/65). Twenty of the 32 patients were responders, 10 non-responders, and 2 not assessable. The most common mutation in non-responders was L858R. Gefitinib responsiveness was only significantly associated with EGFR mutation and adenocarcinoma. The median survival for responder (15.5 months) was much longer than non-responder (9.23 months), though the difference only had marginal significance (p = 0.056). The difference of overall survival between patients with and without EGFR mutation was non-significant (p = 0.7819), mainly due to the short survival of the non-responders with EGFR mutations (median survival = 6.2 months). Our study revealed that the response to gefitinib treatment in NSCLC patients with EGFR mutations could be quite variable even for the same EGFR mutation type. An analysis of the various EGFR mutations and the response patterns was also performed and compared with recently published reports on EGFR mutation and gefitinib responsiveness.

Original languageEnglish
Pages (from-to)311-322
Number of pages12
JournalLung Cancer
Volume53
Issue number3
DOIs
Publication statusPublished - Sep 1 2006
Externally publishedYes

Fingerprint

erbB-1 Genes
Non-Small Cell Lung Carcinoma
Mutation
Survival
Therapeutics
gefitinib
Mutation Rate
Exons
Neoplasms
Adenocarcinoma
Phosphotransferases

Keywords

  • EGFR
  • Gefitinib
  • Lung cancer
  • Mutation
  • NSCLC

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. / Hsieh, Meng Heng; Fang, Yueh Fu; Chang, Wen Cheng; Kuo, Han Pin; Lin, Shinn Yn; Liu, Hui Ping; Liu, Chih Lin; Chen, Hsiu Chi; Ku, Yuan Chieh; Chen, Ya Ting; Chang, Ya Hui; Chen, Ying Tsong; Hsi, Bae Li; Tsai, Shih Feng; Huang, Shiu Feng.

In: Lung Cancer, Vol. 53, No. 3, 01.09.2006, p. 311-322.

Research output: Contribution to journalArticle

Hsieh, MH, Fang, YF, Chang, WC, Kuo, HP, Lin, SY, Liu, HP, Liu, CL, Chen, HC, Ku, YC, Chen, YT, Chang, YH, Chen, YT, Hsi, BL, Tsai, SF & Huang, SF 2006, 'Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer', Lung Cancer, vol. 53, no. 3, pp. 311-322. https://doi.org/10.1016/j.lungcan.2006.06.005
Hsieh, Meng Heng ; Fang, Yueh Fu ; Chang, Wen Cheng ; Kuo, Han Pin ; Lin, Shinn Yn ; Liu, Hui Ping ; Liu, Chih Lin ; Chen, Hsiu Chi ; Ku, Yuan Chieh ; Chen, Ya Ting ; Chang, Ya Hui ; Chen, Ying Tsong ; Hsi, Bae Li ; Tsai, Shih Feng ; Huang, Shiu Feng. / Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. In: Lung Cancer. 2006 ; Vol. 53, No. 3. pp. 311-322.
@article{346342e8d9b146c4bbaa7f9b87a698de,
title = "Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer",
abstract = "Mutational analysis was performed in the kinase domain (exons 18-21) of the EGFR gene on tumor tissues of 65 non-small cell lung cancer (NSCLC) patients who had received gefitinib monotherapy. The association between EGFR gene mutation, gefitinib treatment response, and the overall survival were evaluated. In total, EGFR mutations with complex patterns were identified in 32 tumors. The overall mutation rate was 49.2{\%} (32/65). Twenty of the 32 patients were responders, 10 non-responders, and 2 not assessable. The most common mutation in non-responders was L858R. Gefitinib responsiveness was only significantly associated with EGFR mutation and adenocarcinoma. The median survival for responder (15.5 months) was much longer than non-responder (9.23 months), though the difference only had marginal significance (p = 0.056). The difference of overall survival between patients with and without EGFR mutation was non-significant (p = 0.7819), mainly due to the short survival of the non-responders with EGFR mutations (median survival = 6.2 months). Our study revealed that the response to gefitinib treatment in NSCLC patients with EGFR mutations could be quite variable even for the same EGFR mutation type. An analysis of the various EGFR mutations and the response patterns was also performed and compared with recently published reports on EGFR mutation and gefitinib responsiveness.",
keywords = "EGFR, Gefitinib, Lung cancer, Mutation, NSCLC",
author = "Hsieh, {Meng Heng} and Fang, {Yueh Fu} and Chang, {Wen Cheng} and Kuo, {Han Pin} and Lin, {Shinn Yn} and Liu, {Hui Ping} and Liu, {Chih Lin} and Chen, {Hsiu Chi} and Ku, {Yuan Chieh} and Chen, {Ya Ting} and Chang, {Ya Hui} and Chen, {Ying Tsong} and Hsi, {Bae Li} and Tsai, {Shih Feng} and Huang, {Shiu Feng}",
year = "2006",
month = "9",
day = "1",
doi = "10.1016/j.lungcan.2006.06.005",
language = "English",
volume = "53",
pages = "311--322",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer

AU - Hsieh, Meng Heng

AU - Fang, Yueh Fu

AU - Chang, Wen Cheng

AU - Kuo, Han Pin

AU - Lin, Shinn Yn

AU - Liu, Hui Ping

AU - Liu, Chih Lin

AU - Chen, Hsiu Chi

AU - Ku, Yuan Chieh

AU - Chen, Ya Ting

AU - Chang, Ya Hui

AU - Chen, Ying Tsong

AU - Hsi, Bae Li

AU - Tsai, Shih Feng

AU - Huang, Shiu Feng

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Mutational analysis was performed in the kinase domain (exons 18-21) of the EGFR gene on tumor tissues of 65 non-small cell lung cancer (NSCLC) patients who had received gefitinib monotherapy. The association between EGFR gene mutation, gefitinib treatment response, and the overall survival were evaluated. In total, EGFR mutations with complex patterns were identified in 32 tumors. The overall mutation rate was 49.2% (32/65). Twenty of the 32 patients were responders, 10 non-responders, and 2 not assessable. The most common mutation in non-responders was L858R. Gefitinib responsiveness was only significantly associated with EGFR mutation and adenocarcinoma. The median survival for responder (15.5 months) was much longer than non-responder (9.23 months), though the difference only had marginal significance (p = 0.056). The difference of overall survival between patients with and without EGFR mutation was non-significant (p = 0.7819), mainly due to the short survival of the non-responders with EGFR mutations (median survival = 6.2 months). Our study revealed that the response to gefitinib treatment in NSCLC patients with EGFR mutations could be quite variable even for the same EGFR mutation type. An analysis of the various EGFR mutations and the response patterns was also performed and compared with recently published reports on EGFR mutation and gefitinib responsiveness.

AB - Mutational analysis was performed in the kinase domain (exons 18-21) of the EGFR gene on tumor tissues of 65 non-small cell lung cancer (NSCLC) patients who had received gefitinib monotherapy. The association between EGFR gene mutation, gefitinib treatment response, and the overall survival were evaluated. In total, EGFR mutations with complex patterns were identified in 32 tumors. The overall mutation rate was 49.2% (32/65). Twenty of the 32 patients were responders, 10 non-responders, and 2 not assessable. The most common mutation in non-responders was L858R. Gefitinib responsiveness was only significantly associated with EGFR mutation and adenocarcinoma. The median survival for responder (15.5 months) was much longer than non-responder (9.23 months), though the difference only had marginal significance (p = 0.056). The difference of overall survival between patients with and without EGFR mutation was non-significant (p = 0.7819), mainly due to the short survival of the non-responders with EGFR mutations (median survival = 6.2 months). Our study revealed that the response to gefitinib treatment in NSCLC patients with EGFR mutations could be quite variable even for the same EGFR mutation type. An analysis of the various EGFR mutations and the response patterns was also performed and compared with recently published reports on EGFR mutation and gefitinib responsiveness.

KW - EGFR

KW - Gefitinib

KW - Lung cancer

KW - Mutation

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=33746928318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746928318&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2006.06.005

DO - 10.1016/j.lungcan.2006.06.005

M3 - Article

C2 - 16870303

AN - SCOPUS:33746928318

VL - 53

SP - 311

EP - 322

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -